Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 ELUT | Healthcare | $0.82 | 50.44K | $38.92M | 0.64 | ― | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ELUT | Elutia | 0.82 | 0.07 | 10.07% |
| Name | Price | % Change | |
|---|---|---|---|
| ELUT | $0.82 | +10.07% |
Virtual Meeting to be held on November 20 hosted by Lake Street. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’
Virtual Meeting to be held on November 20 hosted by Lake Street. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the
Elutia Inc. (ELUT) has disclosed a new risk, in the Debt & Financing category. Elutia Inc. faces significant operating constraints under its Avenue loan agreement, which is secured by substantially
Elutia (ELUT) has received the full $8M held in escrow in connection with the sale of its BioEnvelope business to Boston Scientific (BSX). The payment was made following an indemnity
Elutia Inc. (($ELUT)) has held its Q2 earnings call. Read on for the main highlights of the call. Elutia Inc. struck an upbeat tone on its latest earnings call, emphasizing
Elutia ( ($ELUT) ) has shared an announcement. On August 17, 2026, Elutia completed the sale of its SimpliDerm human acellular dermal matrix breast reconstruction business to Cellution Biologics for
Cellution Biologics announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix business from Elutia (ELUT). The acquisition marks Cellution Biologics’ entry into the U.S. reconstructive
Elutia Inc. (ELUT) is scheduled to report 2nd quarter earnings on 08/13/2026, after the market closes. Regarding Q2 estimates, Wall Street analysts expect Elutia Inc. to post earnings of -$0.15
The latest update is out from Elutia ( ($ELUT) ). On August 6, 2026, Elutia Inc. disclosed it had received a Nasdaq notice that its Class A common stock had
Elutia ( ($ELUT) ) has provided an update. On July 16, 2026, Elutia Inc. signed an asset purchase agreement to sell substantially all assets of its SimpliDerm human acellular dermal
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| ELUT | buy | Reiterated | Oct 5, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| ELUT | Mar 3, 2027TBA | $38.92M | $-0.16 | $1.00M | -0.00 | 0.64 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
